PMID- 38251811
OWN - NLM
STAT- MEDLINE
DCOM- 20240201
LR  - 20240202
IS  - 1098-2825 (Electronic)
IS  - 0887-8013 (Print)
IS  - 0887-8013 (Linking)
VI  - 38
IP  - 1-2
DP  - 2024 Jan
TI  - The role of HLA genetic variants in COVID-19 susceptibility, severity, and 
      mortality: A global review.
PG  - e25005
LID - 10.1002/jcla.25005 [doi]
LID - e25005
AB  - BACKGROUND: The COVID-19 pandemic has had a profound global impact, with 
      variations in susceptibility, severity, and mortality rates across different 
      regions. While many factors can contribute to the spread and impact of the 
      disease, specifically human leukocyte antigen (HLA) genetic variants have emerged 
      as potential contributors to COVID-19 outcomes. METHODS: In this comprehensive 
      narrative review, we conducted a thorough literature search to identify relevant 
      studies investigating the association between HLA genetic variants and COVID-19 
      outcomes. Additionally, we analyzed allelic frequency data from diverse 
      populations to assess differences in COVID-19 incidence and severity. RESULTS: 
      Our review provides insights into the immunological mechanisms involving 
      HLA-mediated responses to COVID-19 and highlights potential research directions 
      and therapeutic interventions. We found evidence suggesting that certain HLA 
      alleles, such as HLA-A02, may confer a lower risk of COVID-19, while others, like 
      HLA-C04, may increase the risk of severe symptoms and mortality. Furthermore, our 
      analysis of allele frequency distributions revealed significant variations among 
      different populations. CONCLUSION: Considering host genetic variations, 
      particularly HLA genetic variants, is crucial for understanding COVID-19 
      susceptibility and severity. These findings have implications for personalized 
      treatment and interventions based on an individual's genetic profile. However, 
      further research is needed to unravel the precise mechanisms underlying the 
      observed associations and explore the potential for targeted therapies or 
      preventive measures based on HLA genetic variants.
CI  - (c) 2024 The Authors. Journal of Clinical Laboratory Analysis published by Wiley 
      Periodicals LLC.
FAU - Hoseinnezhad, Taraneh
AU  - Hoseinnezhad T
AD  - Student Research Committee, Bushehr University of Medical Sciences, Bushehr, 
      Iran.
AD  - Department of Hematology, School of Para-Medicine, Bushehr University of Medical 
      Sciences, Bushehr, Iran.
FAU - Soltani, Nasrin
AU  - Soltani N
AUID- ORCID: 0000-0002-1296-4558
AD  - Student Research Committee, Bushehr University of Medical Sciences, Bushehr, 
      Iran.
AD  - Department of Hematology, School of Para-Medicine, Bushehr University of Medical 
      Sciences, Bushehr, Iran.
FAU - Ziarati, Sarina
AU  - Ziarati S
AD  - Student Research Committee, Bushehr University of Medical Sciences, Bushehr, 
      Iran.
FAU - Behboudi, Emad
AU  - Behboudi E
AUID- ORCID: 0000-0002-8971-0775
AD  - Department of Basic Medical Sciences, Khoy University of Medical Sciences, Khoy, 
      Iran.
FAU - Mousavi, Mohammad Javad
AU  - Mousavi MJ
AD  - Department of Hematology, School of Para-Medicine, Bushehr University of Medical 
      Sciences, Bushehr, Iran.
LA  - eng
GR  - 2318/Bushehr University of Medical Sciences/
PT  - Journal Article
PT  - Review
DEP - 20240122
PL  - United States
TA  - J Clin Lab Anal
JT  - Journal of clinical laboratory analysis
JID - 8801384
SB  - IM
MH  - Humans
MH  - *COVID-19/genetics
MH  - SARS-CoV-2/genetics
MH  - Pandemics
MH  - Gene Frequency/genetics
PMC - PMC10829690
OTO - NOTNLM
OT  - COVID-19
OT  - HLA alleles
OT  - SARS-CoV-2
OT  - disease outcomes
OT  - ethnicity
OT  - genetic variation
OT  - severity
OT  - susceptibility
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2024/01/22 12:43
MHDA- 2024/02/01 06:42
PMCR- 2024/01/22
CRDT- 2024/01/22 08:19
PHST- 2023/12/15 00:00 [revised]
PHST- 2023/10/06 00:00 [received]
PHST- 2024/01/02 00:00 [accepted]
PHST- 2024/02/01 06:42 [medline]
PHST- 2024/01/22 12:43 [pubmed]
PHST- 2024/01/22 08:19 [entrez]
PHST- 2024/01/22 00:00 [pmc-release]
AID - JCLA25005 [pii]
AID - 10.1002/jcla.25005 [doi]
PST - ppublish
SO  - J Clin Lab Anal. 2024 Jan;38(1-2):e25005. doi: 10.1002/jcla.25005. Epub 2024 Jan 
      22.